Literature DB >> 23589092

Recent advances in RNA interference therapeutics for CNS diseases.

Pavitra S Ramachandran1, Megan S Keiser, Beverly L Davidson.   

Abstract

Over the last decade, RNA interference technology has shown therapeutic promise in rodent models of dominantly inherited brain diseases, including those caused by polyglutamine repeat expansions in the coding region of the affected gene. For some of these diseases, proof-of concept studies in model organisms have transitioned to safety testing in larger animal models, such as the nonhuman primate. Here, we review recent progress on RNA interference-based therapies in various model systems. We also highlight outstanding questions or concerns that have emerged as a result of an improved (and ever advancing) understanding of the technologies employed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23589092      PMCID: PMC3701762          DOI: 10.1007/s13311-013-0183-8

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  171 in total

1.  siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference.

Authors:  Yuki Naito; Tomoyuki Yamada; Kumiko Ui-Tei; Shinichi Morishita; Kaoru Saigo
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

Review 2.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

3.  MSUT2 is a determinant of susceptibility to tau neurotoxicity.

Authors:  Chris R Guthrie; Lynne Greenup; James B Leverenz; Brian C Kraemer
Journal:  Hum Mol Genet       Date:  2011-02-25       Impact factor: 6.150

4.  Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice.

Authors:  Adebimpe W Kasumu; Xia Liang; Polina Egorova; Daria Vorontsova; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2012-09-12       Impact factor: 6.167

5.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

6.  Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease.

Authors:  Miguel Díaz-Hernández; Jesús Torres-Peraza; Alejandro Salvatori-Abarca; María A Morán; Pilar Gómez-Ramos; Jordi Alberch; José J Lucas
Journal:  J Neurosci       Date:  2005-10-19       Impact factor: 6.167

7.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

8.  Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.

Authors:  Edgardo Rodríguez-Lebrón; Cynthia M Gouvion; Steven A Moore; Beverly L Davidson; Henry L Paulson
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

9.  Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation.

Authors:  A Matilla; E D Roberson; S Banfi; J Morales; D L Armstrong; E N Burright; H T Orr; J D Sweatt; H Y Zoghbi; M M Matzuk
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

10.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

Authors:  Ryan L Boudreau; Jodi L McBride; Inês Martins; Shihao Shen; Yi Xing; Barrie J Carter; Beverly L Davidson
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

View more
  9 in total

Review 1.  Oligonucleotide therapeutics in neurodegenerative diseases.

Authors:  Daniel R Scoles; Stefan M Pulst
Journal:  RNA Biol       Date:  2018-06-01       Impact factor: 4.652

2.  Non-viral Vector Mediated RNA Interference Technology for Central Nerve System Injury.

Authors:  Christian Macks; Jeoung Soo Lee
Journal:  DNA RNA Nanotechnol       Date:  2016-08-25

Review 3.  Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.

Authors:  Megan S Keiser; Holly B Kordasiewicz; Jodi L McBride
Journal:  Hum Mol Genet       Date:  2015-10-26       Impact factor: 6.150

Review 4.  The role of the immune system in triplet repeat expansion diseases.

Authors:  Marta Olejniczak; Martyna O Urbanek; Wlodzimierz J Krzyzosiak
Journal:  Mediators Inflamm       Date:  2015-03-22       Impact factor: 4.711

5.  A brief perspective on neural cell therapy.

Authors:  Jan Pruszak
Journal:  Mol Cell Ther       Date:  2014-01-08

Review 6.  Mechanisms of RNA-induced toxicity in CAG repeat disorders.

Authors:  R Nalavade; N Griesche; D P Ryan; S Hildebrand; S Krauss
Journal:  Cell Death Dis       Date:  2013-08-01       Impact factor: 8.469

Review 7.  Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems.

Authors:  Daniyah A Almarghalani; Sai H S Boddu; Mohammad Ali; Akhila Kondaka; Devin Ta; Rayyan A Shah; Zahoor A Shah
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

8.  Inducible and combinatorial gene manipulation in mouse brain.

Authors:  Godwin K Dogbevia; Ricardo Marticorena-Alvarez; Melanie Bausen; Rolf Sprengel; Mazahir T Hasan
Journal:  Front Cell Neurosci       Date:  2015-04-21       Impact factor: 5.505

9.  IGFBP‑rP1‑silencing promotes hypoxia‑induced angiogenic potential of choroidal endothelial cells via the RAF/MEK/ERK signaling pathway.

Authors:  Shuting Zhu; Hong Wang; Zhihua Zhang; Mingming Ma; Zhi Zheng; Xun Xu; Tao Sun
Journal:  Mol Med Rep       Date:  2020-10-11       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.